http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2017258716-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_26662a4f406ebe4b6179634634f6a429
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61M37-0092
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B2090-378
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61M2037-0007
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1075
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61M37-0092
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61N7-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-704
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61M37-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-107
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-704
filingDate 2015-08-03-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_38c03250b79f73fa1b4180db34a0e39e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_de170c89d7daed019b2bbc43d705282f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a9efd6f10935761ed76c0bce7cd25e34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2cd583d5df79f8daaf84e2c38d680534
publicationDate 2017-09-14-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber US-2017258716-A1
titleOfInvention Anti-cancer agent for use in combination therapy of high intensity focused ultrasound therapy and anti-cancer agent therapy
abstract The present invention provides a cancer treatment method in which side effects are inhibited. Specifically, in a combination therapy of a high intensity focused ultrasound therapy at an irradiation intensity of 320 to 700 W/cm 2 and an anti-cancer agent therapy, an anti-cancer agent containing an anthracycline is used such that the anthracycline in a dose of 0.5 to 7.5 mg/kg body weight is administered to a cancer patient.
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2664597-C1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2703330-C2
priorityDate 2014-08-04-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395412
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395471
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3763
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419507060
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID31703
http://rdf.ncbi.nlm.nih.gov/pubchem/taxonomy/TAXID1950
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID451030023
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID452169947
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419535365
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395318
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID58076462
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID30323
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419504051
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID41867
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID65348
http://rdf.ncbi.nlm.nih.gov/pubchem/anatomy/ANATOMYID1950
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419504230
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226399747

Total number of triples: 44.